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Mutations in BCAP31 Cause a Severe X-Linked Phenotype
with Deafness, Dystonia, and Central Hypomyelination
and Disorganize the Golgi Apparatus
Pierre Cacciagli,1,2,3 Julie Sutera-Sardo,1,2 Ana Borges-Correia,1,2 Jean-Christophe Roux,1,2 Imen Dorboz,4
Jean-Pierre Desvignes,1,2 Catherine Badens,1,2,3 Marc Delepine,5 Mark Lathrop,5,6 Pierre Cau,1,2,7
Nicolas Le´vy,1,2,3 Nadine Girard,2,8 Pierre Sarda,9 Odile Boespflug-Tanguy,4,10 and Laurent Villard1,2,*
BAP31 is one of the most abundant endoplasmic reticulum (ER) membrane proteins. It is a chaperone protein involved in several path-
ways, including ER-associated degradation, export of ER proteins to the Golgi apparatus, and programmed cell death. BAP31 is encoded
by BCAP31, located in human Xq28 and highly expressed in neurons. We identified loss-of-function mutations in BCAP31 in seven in-
dividuals from three families. These persons suffered from motor and intellectual disabilities, dystonia, sensorineural deafness, and
white-matter changes, which together define an X-linked syndrome. In the primary fibroblasts of affected individuals, we found that
BCAP31 deficiency altered ER morphology and caused a disorganization of the Golgi apparatus in a significant proportion of cells. Con-
trary to what has been described with transient-RNA-interference experiments, we demonstrate that constitutive BCAP31 deficiency
does not activate the unfolded protein response or cell-death effectors. Rather, our data demonstrate that the lack of BAP31 disturbs
ER metabolism and impacts the Golgi apparatus, highlighting an important role for BAP31 in ER-to-Golgi crosstalk. These findings pro-
vide a molecular basis for a Mendelian syndrome and link intracellular protein trafficking to severe congenital brain dysfunction and
deafness.In the search for mutations causing X-linked intellectual
disability (XLID), we used next-generation sequencing
technologies to sequence the X chromosome exome in
11 unrelated male individuals suffering from severe intel-
lectual disability. These individuals were selected because
they were severely affected, and either they had a clinical
presentation that did not correspond to a known syn-
drome or molecular tests failed to detect a mutation in
known genetic causes of XLID. Most of them displayed
additional clinical signs involving the CNS, such as deaf-
ness or congenital microcephaly. In order to sequence
the X chromosome exome, we captured exonic sequences
with the Agilent SureSelect Human Exome V3 Kit and per-
formed sequencing with the Illumina Hiseq pipeline v.1.5
at the Centre National de Ge´notypage (Evry), the French
national genotyping center. Sequences were mapped to
the human reference genome (hg19 assembly of the
UCSC Genome Browser) with the commercial software
CLCBIO Genomics Workbench v.4.9. We also performed
SNP detection with CLCBIO and used an additional filter
to select the variants located on the human X chromo-
some. We selected variants with a minimum quality of
30 and a minimum average quality of surrounding bases
of 20. All SNPs were filtered against dbSNP132. We dis-
carded variants for which we had fewer than ten reads
and those located outside coding sequences or farther1INSERM UMR-S 910, Marseille 13385, France; 2Faculte´ de Me´decine Timo
Ge´ne´tique Me´dicale, Hoˆpital d’Enfants de la Timone,Marseille 13385, France; 4
Debre´, Paris 75019, France; 5Commissariat a` l’Energie Atomique, Institut Ge´nom
Dausset, Centre d’E´tude du Polymorphisme Humain, Paris 75010, France; 7La
13385, France; 8Service de Neuroradiologie, Hoˆpital de La Timone, Marseille 1
leneuve, Montpellier 34295, France; 10Service de Neurope´diatrie et Maladies M
Robert Debre´, Assistance Publique – Hoˆpitaux de Paris, Paris 75019, France
*Correspondence: laurent.villard@univ-amu.fr
http://dx.doi.org/10.1016/j.ajhg.2013.07.023. 2013 by The American Societ
The Americanthan 55 nucleotides from an exon. Possible disease-
causing sequence variants were analyzed by several bioin-
formatics tools, such as UMD-HTS,1 MutationTaster, the
National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server, and the Human
Gene Mutation Database (Table S1, available online).
In one of the affected individuals (III.2, family 1), who
also presented with sensorineural deafness and dystonia,
we identified a c.1942A>G mutation in exon 4 of
BCAP31 (MIM 300398), encoding B-cell-receptor-associ-
ated protein 31 (BAP31), in Xq28 (Figure 1). Amplification
and sequencing of BCAP31 transcripts in the primary
fibroblasts of the affected individual revealed that
the c.1942A>G mutation (RefSeq accession number
NM_001139441.1) activates a cryptic splice site located at
positions 42 and 43 relative to exon 4 of BCAP31 and
results in a transcript that is predicted to encode a trun-
cated BAP31 (p.Ile64fs*25) (Figures S1A and S1B). We
measured the amount of BCAP31 transcript in the fibro-
blasts of individual F1-III.2 and found it to be 7% of the
wild-type level, suggesting that the mutant transcript is a
substrate for nonsense-mediated mRNA decay (data not
shown). There is no antibody available to detect the N-ter-
minal region of BAP31, so we therefore do not know
whether a truncated peptide could be produced by the
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Figure 1. Pedigrees and Identified Mutations
(A) Pedigrees of the three families show the seven affected individuals and female carriers of a BCAP31 mutation.
(B) Schematic representation of the human chromosome Xq28 region containing BCAP31 and flanking SLC6A8 and ABCD1. Exon
numbers are provided, and arrows indicate the transcription orientation (cen, centromere; tel, telomere). UTRs are represented by
open boxes, and the alternative 30 UTR of SLC6A8 is hatched. The three mutations are indicated below the genes. The Xq28 deletion
is numbered according to HGVS nomenclature: RefSeq NM_005629.3 for SLC6A8 and NM_001139441 for BCAP31.showed that the c.1942A>G mutation leads to the
absence of normal BAP31 in the fibroblasts of affected per-
sons (Figure S1C).
BAP31 is a chaperone and is one of the most abundant
endoplasmic reticulum (ER) membrane proteins.2 This
ubiquitous 31 kDa protein has a role in the export of
secreted proteins from the ER,3,4 the recognition of abnor-
mally folded proteins, and their targeting to the ER-associ-
ated-degradation (ERAD) pathway.5,6 BAP31 also serves as
a cargo receptor for the export of transmembrane pro-
teins.5 It is highly abundant in neurons.7
We screened BCAP31 for mutations in 29 male probands
presenting with severe intellectual disability, dystonia, and
sensorineural deafness, a phenotype similar to that of
affected males in family 1. Two additional BCAP31 muta-
tions were identified. The first mutation was identified in
a family with four affected males, and the second was
found in a family with a single affected male (families 2
and 3, respectively, Figure 1A). We found a deletion of
BCAP31 exon 8 in family 2 and a truncating c.97C>T
(p.Gln33*) mutation in exon 3 in family 3 (Figure 1B and
Figure S1A). The three mutations were inherited through
carrier females who do not have intellectual disability.
Clinical cerebral MRI and sample collection from affected
individuals were performed at the Centre de Re´fe´rence
Maladies Rares ‘‘Leucodystrophie’’ (LeukoFrance network,580 The American Journal of Human Genetics 93, 579–586, SeptembLeucoEpimar, Leukobiobank) with the ethical agreement
of the Comite´ de Protection des Personnes Sud-Est VI
(no. AU788), the Commission National de l’Informatique
et des Liberte´s (no. 1406552), and the Agence Franc¸aise
de Se´curite´ Sanitaire des Produits de Sante´ (no. B90298-
60), and signed informed consent was obtained from the
affected individuals or their legal guardians.
In order to precisely characterize the deletion present in
family 2, we performed a series of PCR amplifications by
using primers located 50 and 30 to the deleted exon in
BCAP31 to amplify the deletion junction fragment from
the DNA of affected individuals in that family (Figure S1D).
Sequencing of the junction fragment revealed that the
deletion spans 5,344 bp and results in the loss of exon 8
of BCAP31 and 248 bp of the 30 UTR of the neighboring
SLC6A8 (MIM 300036), encoding a creatine transporter
(Figure 1B). SLC6A8mutations cause cerebral creatine defi-
ciency syndrome (MIM 300352), and affected males have
intellectual disability. To assess the potential involvement
of the 30 UTR deletion of SLC6A8 in the phenotype of the
affected individuals in family 2, we measured the amount
of SLC6A8 mRNA in their fibroblasts and found that it
was reduced by 54% (Figure S1E). However, the creatine
peaks on proton magnetic resonance spectroscopy were
found to be normal in the only living male individual
in this family (IV.1, data not shown). The expression ofer 5, 2013
Figure 2. Phenotype of the Affected Individuals
(A) Facial dysmorphic features observed in the different affected members of the three families. Note the dystonic posture of the upper
limbs of individuals F1-III.3 and F3-III.1.
(B) Sagittal cerebral MRI sequence of person F1-III.2 at 11 months of age shows the atrophy of the cerebellar vermis (white arrow) (a).
Axial cerebral MRI of individual F2-IV.1 at 6.5 years of age shows a mild abnormal hyperintense signal on the T2 sequence in the
parieto-occipital white matter (b) and a normal hyperintense signal on the T1 sequence (c) (open white arrows), suggesting poor
myelination.an SLC6A8 transcript (Ensembl reference sequence
ENST00000597046.1) with a shorter 30 UTR that is not
deleted in family 2 (Figure 1B) might account for this
observation and for the fact that SLC6A8 transcripts were
present at 46% of the wild-type levels in the fibroblasts
of the affected individuals. We conclude that SLC6A8 is
not involved in the phenotype of the affected individuals
in family 2. In addition, the similarity of the clinical pre-
sentation among the three families (two of which were
devoid of any SCL6A8 anomaly) further supports this
conclusion. Indeed, comparison of the clinical phenotypes
in the three affected families, comprising a total of seven
affected individuals, defines an XLID syndrome consisting
of severe motor and intellectual disabilities, early dystonia,
sensorineural deafness, and hypomyelinating white-
matter changes associated with failure to thrive, micro-
cephaly, and facial dysmorphism (Figure 2 and Table 1).
Death occurred during the first years of life, suddenly, or,
in four cases, during a febrile episode. Progressive aggrava-
tion of the phenotype with cerebral atrophy was observed
in two individuals, who died at the end of adolescence.
The only surviving person improved clearly after 3 years
of age and remained stable at the last examination at age
13. If one considers the clinically homogeneous cohortThe Americancomposed of family 1 (coming from the exome sequencing
project) and the 29 families screened in a second phase
because they had a similar phenotype, mutations in
BCAP31 were found in 10% (3/30). This relatively high
detection rate suggests that BCAP31 mutations might not
be rare in males suffering from deafness, dystonia, and
white-matter changes.
Approximately 30% of all proteins in eukaryotic cells are
targeted to the ER to be folded and to receive posttransla-
tional modifications.8 During translation, the nascent
polypeptide enters the reticulum via the translocon, a
pore-forming complex. Several translocon-associated pro-
teins ensure that polypeptides entering the ER fold
properly. If incorrect folding is detected, for example in
proteins containing missense substitutions, a mechanism
of retrograde transport operating from the ER lumen to
the cytoplasm targets the protein for degradation by the
proteasome after polyubiquitinylation.9 If the cell cannot
maintain an acceptable level of misfolded proteins, it
will launch apoptosis programs and die.10 The three muta-
tions identified in BCAP31 are probable loss-of-function
alleles that abolish the production of normal BAP31
(Figure S1C). Given the role and cellular distribution
of BAP31, we next examined ER morphology in theJournal of Human Genetics 93, 579–586, September 5, 2013 581
Table 1. Summary of the Clinical and MRI Features Identified in the Affected Individuals
Family 1 Family 2 Family 3
III.2 III.3 III.5 III.6 III.7 IV.1 III.1
Age at last exam 22 years 11 years NA 10 months 12 months 13 years 3 years
Age of onset congenital congenital congenital 6 weeks 6 weeks congenital congenital
Age at death 24 years 13 years 7 months (sudden) 1 year (fever) 2 years (sudden) living 3 years (fever)
Deafness (onset) þ (1 year) þ (1 year) NA þ (1 year) þ (1 year) þ (normal at 6 weeks,
70 db at 7 months,
0 db at 3 years)
þ (5 months; 20 db at
8 months)
Facial dysmorphism þþ þ NA þ þ þ þ/
Best Acquisitions
Motor (acquired at) none none none none head (12 months) head (6 months), sitting
(5 years), autonomous
wheelchair (8 years)
head (1 year; lost at 1.5 years)
Cognitive none none none none none simple sign language and
scribbling
none
Neurological Signs
Ocular congenital strabismus congenital strabismus,
abnormal eye movements
NA optic atrophy congenital
strabismus
congenital strabismus,
optic atrophy
congenital strabismus
Dystonia (onset) þþ þþ NA þþþ þþþ þþ (10 months) þþþ (6 months)
Seizures (onset) þ (4 years) þ NA none none þ (8 years) none
Other pyramidal signs, quadriplegia,
unexplained episodic fever,
aggressiveness
pyramidal signs, quadriplegia,
unexplained episodic fever
NA pyramidal signs,
quadriplegia
pyramidal signs,
quadriplegia
pyramidal signs, paraplegia,
unexplained episodic fever,
hyperactivity
pyramidal signs, quadriplegia,
unexplained episodic fever
Growth
Failure to thrive þþþ (IUGD, weight 7 SDs,
height 8 SDs)
þþþ (IUGD, weight 6 SDs,
height 5 SDs)
NA þ þ þþþ (IUGD, weight and
height 3 SDs at 0–3 years
and 2 SDs at >3 years)
þ (normal at birth, weight
and height 2 SDs at >1 year)
Microcephaly þþþ (5 SDs) þþþ (5 SDs) NA NA NA þ (3 SDs at 2 months, 2
SDs at 2 years)
þþ (2 SDs at 0–6 months,
3 SDs at >6 months)
MRI
White matter
(performed at)
NP periventricular
hypomyelination (11 years)
NP NP NP periventricular
hypomyelination (5.6 years)
diffuse hypomyelination
(2.5 years)
Atrophy NP cerebral cortex, cerebellum NP NP NP 0 corpus callosum, frontal lobe,
white matter
Abbreviations are as follows: þþþ, severe; þþ, moderate; þ, mild; þ/, very mild; IUGD, intrauterine growth delay; NA, not available; and NP, not performed.
5
8
2
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
3
,
5
7
9
–
5
8
6
,
S
e
p
te
m
b
e
r
5
,
2
0
1
3
Figure 3. BAP31-Deficient Fibroblasts Have Abnormal Morphology
(A) Immunohistochemistry performed on fibroblasts of two control individuals (C1 and C2), individual III.2 from family 1 (F1-III.2),
individual IV.1 from family 2 (F2-IV.1), and individual III.1 from family 3 (F3-III.1) with an antibody against CALR (1:200, Stressgen
ADI-SPA-600-F) (left panels) or HSPA5 (1:200, Abcam ab151269) (right panels). These images reveal the abnormal size and shape of
BAP31-deficient fibroblasts compared with control fibroblasts. Cells were stained with DAPI for visualization of nuclear DNA. Scale
bars represent 25 mm.
(B) Quantification of the area and perimeter of control and affected individuals’ fibroblasts immunolabeled with CALR and shown in (A)
demonstrates the statistically different values (*p < 0.0001, Student’s t test) between the fibroblasts of the two control individuals and
the three affected individuals. For each fibroblast, a region of interest delineated with ImageJ software defined the cell boundaries. The
program measured the area and the perimeter expressed in square micrometers and micrometers, respectively. We measured the
morphometric parameters of randomly selected fibroblasts (104 cells were analyzed for C1, 103 for C2, 80 for individual F1-III.2, 82
for individual F2-IV.1, and 60 for individual F3-III.1). Error bars represent the SEM.fibroblasts of the affected individuals. We labeled calreticu-
lin (CALR), a soluble protein chaperone located in the ER
lumen, where it enables the correct folding of nascent
proteins. CALR labeling revealed a swollen aspect in all
BAP31-deficient fibroblasts (Figure 3A). To exclude a
possible CALR-specific observation, we repeated these ex-
periments by using heat shock 70 kDa protein 5 (HSPA5,
also known as glucose-regulated protein 78 [GRP78]),
another abundant ER chaperone (Figure 3A), and we
confirmed that the size of the mutant fibroblasts was
increased (Figure 3B).The AmericanWe reasoned that, in the absence of BAP31, ERAD
dysfunction might lead to the accumulation of misfolded
proteins in the ER. We used the DF508 (c.1521_
1523delCTT [RefSeq NM_000492.3]) altered version of
cystic fibrosis transmembrane conductance regulator
(CFTR), the most frequent cause of cystic fibrosis (MIM
219700), as an ERAD substrate whose degradation involves
BAP31.11,12 Transfection with pEGFP-DF508CFTR was
performed, and fibroblasts were grown for 24 hr after trans-
fection. BCAP31 mutations appeared to lead to the pres-
ence of increased amounts of EGFP-DF508CFTR (Figure S2),Journal of Human Genetics 93, 579–586, September 5, 2013 583
as would be expected from reduced ERAD activity.
However, the difference between affected and control
fibroblasts was not statistically significant when the fluo-
rescence was quantified by image analysis (Figure S2A) or
flow cytometry (Figure S2B). These findings suggest that
the BCAP31 mutations identified in the three families do
not lead to a massive accumulation of misfolded proteins
within the ER, contrary to what was found via transient
RNAi experiments.11,12 Most likely, BAP31-independent
pathways are able to cope with the misfolded proteins pre-
sent and thus avoid an accumulation of unwanted proteins
in the ER.
Next, we tested whether the unfolded protein response
(UPR) was activated in BAP31-deficient fibroblasts. We
measured the transcript levels of three genes whose expres-
sion is known to be increased upon UPR activation:10
DDIT3 (MIM 126337), HSPA5 (MIM 138120), and XBP1
(MIM 194355). Unexpectedly, we found that the UPR
was not activated in the affected individuals’ fibroblasts,
although these cells were able to activate their UPR when
treated with ER-stress inducer thapsigargin (Figure S3A).
Accordingly, levels of HSPA5 and XBP1 were unchanged
in BAP31-deficient fibroblasts (Figure S3B). DDIT3 levels
could not be tested because of the poor specificity of the
DDIT3 antibody in immunoblot experiments.
In addition toUPR and ERAD, BAP31was recently shown
to have a role in cell death via an interaction with the pro-
tein product of FIS1.13 We also investigated this aspect to
determine whether our human BAP31-deficient fibroblasts
were launching apoptosis programs.We found no evidence
of cell death in the fibroblasts lacking BAP31. The mito-
chondrial-respiratory-chain activities in the muscle of
person F3-III.1 were normal (data not shown), and the
mitochondrial network displayed a normal morphology
in all affected fibroblasts (Figure S4A). In addition, immu-
noblot analysis failed to detect cleaved caspase-3, a medi-
ator of apoptotic cell death, in BAP31-deficient fibroblasts
(Figure S4B). From these data, we conclude that the pheno-
type of the individuals carrying aBCAP31mutationwasnot
caused by exacerbated cell death.
BAP31 was shown to serve as a cargo receptor for the
export of transmembrane proteins.5 Given that the ER
was abnormal in BAP31-deficient fibroblasts, we wondered
whether the Golgi apparatus morphology was preserved.
To visualize the Golgi apparatus in affected fibroblasts,
we used an antibody raised against GOLGA2, a membrane
protein involved in the maintenance of the Golgi appa-
ratus structure.14 We found that the Golgi apparatus was
disorganized in up to 29.5% of BAP31-deficient fibroblasts
(Figures 4A and 4B). To better observe the cellular ultra-
structure, we studied these cells by using electron micro-
scopy and confirmed that a significant proportion of
BAP31-deficient fibroblasts had an unusually large ER
and abnormal Golgi morphology. Strikingly, we found
that the mutant fibroblasts contained large cytoplasmic
vesicles partially filled with electron-dense inclusions
(Figure 4C). These vesicles possibly originated from the584 The American Journal of Human Genetics 93, 579–586, Septembdisorganization of the Golgi apparatus, given that they
were frequently observed in close vicinity to residual
Golgi-like structures.
Taken together, our results support the notion that
BAP31 has a role in ER-to-Golgi exchanges and that this
function cannot be compensated in human cells. In
human BAP31-deficient fibroblasts, misfolded proteins
do not massively accumulate and there is no activation
of either the UPR or cell-death programs. A disorganized
Golgi apparatus is predicted to have major consequences
for the production of plasma membrane or secreted
proteins. The seven affected individuals’ phenotype,
combining intellectual disability, dystonia, and sensori-
neural deafness, demonstrates that this is particularly dele-
terious for the CNS. In the brain of the BAP31-deficient
individuals, we observed white-matter changes reminis-
cent of those observed in hypomyelinating leukodystro-
phies,15 confirming the key role of ER protein trafficking
in the myelination process.16 BCAP31 is flanked by two
genes: SLC6A8 on its centromeric side and ABCD1 (MIM
300371) on its telomeric side. Large deletions involving
BCAP31 and ABCD117,18 or SCL6A8 and BCAP31 have
been reported.19 Deletions involving ABCD1 and BCAP31
have been reported in four cases and have been given the
acronym CADDS (contiguous ABCD1 DXS1357E deletion
syndrome [MIM 300475]). In one case, however, the dele-
tion extended over seven genes in Xq28,18 thereby compli-
cating the interpretation of the clinical findings. The
affected persons suffered from neonatal hypotonia, failure
to thrive, cholestatic liver disease, and white-matter abnor-
malities (ranging from mild hypomyelination to neuronal
heterotopias) not described in adrenoleukodystrophy
(MIM 300100). Seizures were inconstant. The four individ-
uals described with CADDS died before the first year of age.
Facial dysmorphism was described in a single case. They all
had sensorineural deafness. Deletions of SLC6A8 and
BCAP31 cause dystonia, profound intellectual disability,
mild liver dysfunction, sensorineural deafness, and myeli-
nation delay.19 These clinical signs, also found in our series
of seven BAP31-deficient individuals, do not belong to the
clinical picture of individuals presenting with a dysfunc-
tion of either SLC6A8 or ABCD1; these latter individuals
display, respectively, cerebral creatine deficiency syndrome
or adrenoleukodystrophy. It is very likely that the liver
dysfunction reported in persons carrying large deletions
involving BCAP31 and ABCD1 or SCL6A8 and BCAP31
can be attributed to BCAP31 loss. Four affected individuals
in our families harboring mutations in BCAP31 demon-
strated transitory episodes of a 2- to 3-fold increase of liver
transaminase levels during banal febrile illnesses. How-
ever, in contrast to previous reports,17,18 liver ultrasound
did not detect any abnormalities in the affected individ-
uals we describe.
The identification of loss-of-function mutations in
BCAP31 provides the molecular basis of a Mendelian syn-
drome and links ER-to-Golgi exchange to severe congenital
brain dysfunction and deafness.er 5, 2013
Figure 4. The Golgi Apparatus Is Disorga-
nized in a Large Proportion of BAP31-Defi-
cient Fibroblasts
(A) Representative images show the
abnormal structure of the Golgi apparatus
in BAP31-deficient fibroblasts. The typical
bean-shaped perinuclear Golgi structure
observed in control fibroblasts was lost in a
large proportion of BAP31-deficient fibro-
blasts, where it was replaced by small
patches of GOLGA2-positive structures scat-
tered in the cytoplasm. Immunohistochem-
istry was performed on fibroblasts from
two control individuals (C1 and C2),
individual III.2 from family 1 (F1-III.2), indi-
vidual IV.1 from family 2 (F2-IV.1), and indi-
vidual III.1 from family 3 (F3-III.1) with an
antibody specific to GOLGA2 (green)
(1:200, Sigma G7295). The fibroblasts were
stained with DAPI for visualization of
nuclear DNA. Scale bars represent 25 mm.
(B) Percentage of fibroblasts showing a
severely perturbed Golgi apparatus mor-
phology in control samples and in the
fibroblasts of the three affected individuals
(*p < 0.01, Chi-square test; 100 cells were
counted in each of two experiments for
each condition).
(C) Representative electron-microscopy
images reveal the ultrastructure of control
fibroblasts (i and ii) and BAP31-deficient
fibroblasts in individuals F1-III.2 (iii and
iv), F2-IV.1 (v and vi), and F3-III.1 (vii and
viii). The cells were washed, fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.4), postfixed in 1% osmium tetroxide,
scraped, and centrifuged, and the pellet was
dehydrated in graded alcohol solutions and
embedded in SPURR low-viscosity medium.
Ultrathin sections (50–60 nm) were counter-
stained with uranyl acetate and lead citrate
before observation with a JEOL JEM1400
electron microscope at 80 kV. Images were
obtained with a MegaView III camera (Soft
Imaging System). The affected individuals’
fibroblasts contained an enlarged ER (black arrows) and numerous vesicles containing electron-dense material (asterisks) and lost
the normal structure of their Golgi apparatus (white arrows in control fibroblasts). N ¼ nucleus. Scale bars represent 2 mm (iv, v,
and vi) or 1 mm (i, ii, iii, vii, and viii).Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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